Plasmablastic lymphoma
diseaseOn this page
Also known as PBLPLBL
Summary
Plasmablastic lymphoma (MONDO:0017347) is a cancer and 14 clinical trials. Top therapeutic interventions include cyclophosphamide anhydrous, belantamab mafodotin, and ixazomib citrate. A subtype of Epstein-Barr virus-associated lymphoproliferative disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 14
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | plasmablastic lymphoma |
| Mondo ID | MONDO:0017347 |
| MeSH | D000069293 |
| Orphanet | 289666 |
| DOID | DOID:0080779 |
| ICD-11 | 803046659 |
| NCIT | C7224 |
| SNOMED CT | 724648008 |
| UMLS | C3472614 |
| MedGen | 483338 |
| GARD | 0012125 |
| MedDRA | 10065039 |
| Is cancer (heuristic) | yes |
Also known as: PBL · Plasmablastic lymphoma · PLBL
Data availability: 8 cell lines.
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › virus associated tumor › Epstein-Barr virus-related tumor › Epstein-Barr virus-associated lymphoproliferative disorder › plasmablastic lymphoma
Related subtypes (10): primary central nervous system lymphoma, Hodgkins lymphoma, Burkitt lymphoma, Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly, diffuse large B-cell lymphoma with chronic inflammation, systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood, hydroa vacciniforme-like lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, extranodal nasal NK/T cell lymphoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 14.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 4 |
| PHASE1 | 4 |
| PHASE1/PHASE2 | 3 |
| Not specified | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02797470 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant |
| NCT03038672 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas |
| NCT04915248 | PHASE2 | RECRUITING | Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. |
| NCT01092182 | PHASE2 | COMPLETED | Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma |
| NCT01193842 | PHASE1/PHASE2 | COMPLETED | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas |
| NCT02481310 | PHASE1/PHASE2 | UNKNOWN | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma |
| NCT04676360 | PHASE2 | TERMINATED | Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma |
| NCT05389423 | PHASE1 | RECRUITING | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas |
| NCT05544019 | PHASE1 | RECRUITING | Study of SGR-1505 in Mature B-Cell Neoplasms |
| NCT07113496 | PHASE1 | NOT_YET_RECRUITING | RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies |
| NCT07332507 | PHASE1 | NOT_YET_RECRUITING | Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma |
| NCT04139304 | EARLY_PHASE1 | RECRUITING | A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma |
| NCT05663502 | Not specified | RECRUITING | Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers |
| NCT06781359 | Not specified | RECRUITING | Study on Plasmablastic Lymphoma Patients |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CYCLOPHOSPHAMIDE ANHYDROUS | 4 | 4 |
| BELANTAMAB MAFODOTIN | 4 | 1 |
| IXAZOMIB CITRATE | 4 | 1 |
| TECLISTAMAB | 4 | 1 |
| VORINOSTAT | 4 | 1 |
| VARLILUMAB | 2 | 1 |
| SGR-1505 | 1 | 1 |
| CHEMBL1813256 | 0 | 1 |